Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025

Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025

Over 6,500 unique ECPs prescribed VIZZ; more than 55% have prescribed multiple times in Q4 2025

 LENZ Therapeutics, Inc. , a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia,  reported certain preliminary unaudited financial results for the fourth quarter ended December 31, 2025 and recent corporate updates.

“We are proud of the strong execution delivered in our first quarter of launch, as the team established a solid foundation of awareness, confidence, and willingness to prescribe VIZZ across the eye care professional community,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “More than 6,500 eye care professionals have already written a prescription for VIZZ, the majority of whom prescribed multiple times, signaling early confidence in VIZZ as a convenient and effective alternative to reading glasses. At the same time, over 20,000 prescriptions were filled during our first quarter of launch, exceeding our expectations and reinforcing the early momentum behind VIZZ. Building on this progress, and together with our campaign spokesperson Sarah Jessica Parker, we look forward to launching the VIZZ DTC campaign this quarter.”

Fourth Quarter 2025 Commercial Highlights

• First commercial product sale of VIZZ in October 2025, the first and only aceclidine-based eye drop for the treatment of presbyopia
• Full multi-channel access established through epharmacy and substantially all retail pharmacies by mid-November 2025
• VIZZ net product revenue of approximately $1.6 million in Q4 2025
• Over 20,000 prescriptions filled through Q4 2025
• Rapid uptake by prescribing ECPs with over 6,500 unique prescribing ECPs; more than 55% prescribed multiple times in Q4 2025

Additional Recent Corporate Updates

• In January 2026, the Company announced an exclusive commercialization partnership for VIZZ with Lunatus in the Middle East. Under the terms of the agreement, LENZ will receive upfront, regulatory and commercial milestone payments, in addition to a significant share of revenue generated in the region through a pre-determined minimum product supply price. This agreement represents the fourth commercialization partnership for VIZZ outside the United States.